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Poster Session I 7110.6 days. Conclusions: Despite known dismal prognosis, 3 out of
the 5 patients treated in our center are well at a follow-up of more
than 2 years. One of these survivors is an infant with metastatic
ATRT. There was no TRM or severe morbidity. This approach
with HDC and AHSCT needs to be validated in larger studies.
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Purpose: Hematopoietic stem cell transplantation (HSCT) has
been successfully applied to some forms of inborn errors in metab-
olism (IEM). However, its long term effects have varied according
to the type and the stage of disease. Among mucopolysaccharidosis
(MPS), the efficacy of HSCT in type II (Hunter’s disease) has been
controversial.
A nationwide survey was performed to collect data on transplant
outcomes and long term clinical effects in HSCT for IEM in Japan,
in order to clarify the problems and the efficacies in those diseases. A
special focus was put on Hunter’s disease, the most common form
among Asian MPS patients, and a detailed comparison was made
with patients to whom HSCT had not been applied. Patients:
Data were collected on 141 patients from 35 institutes. HSCT
were done during the period between 1985 and 2004, and the min-
imum follow-up was one year in long term survivors.
Diseases: MPS 72, adrenoleucodystrophy (ALD);38, I-cell dis-
ease;6, metachromatic leucokystrophy (MLD);7, others;14
Sex: M/F 113/28
Age at first HSCT:median 4 years old (0–15)
Donors (1st HSCT): siblings;63, parents;11, unrelated;67
HLA compatibility (1st HSCT): match;108, mismatch;32, un-
known;1
Cell sources (1st HSCT): BM;113, PB;2, CB;22 Transplant
Outcomes: Survival: alive;114 (81%), dead;27(19%)
Overall survival (OS) rates according to disease: MPS(N 5
71);87%, ALD(N 5 38);76%, Gaucher(N 5 4);75%, MLD(N 5
7);43%, I-cell(N 5 6);22%. (P 5 0.006)
OS according to donor: sibling(N 5 62);87%, UBM(N 5
48);80%, UCB(N 5 19);68%, parents(N 5 11);64%. (P 5 0.002)
OS according to HLA compatibility: match(N5 108);79%, mis-
match(N 5 32);69%. (P 5 0.008)
OS according to cell source: BM(N 5 117);79%, CB(N 5
22);58%. (P\ 0.001) Clinical Effects: Long term clinical effects
varied from disease to disease and from patient to patient. Patients
who were transplanted in early stages have benefited more than pa-
tients transplanted in advanced stages.
A comparison in Hunter’s disease between 44 transplanted pa-
tients and with untransplanted patients revealed that quality of life
improved rapidly following HSCT due to normalization in range
of joint movement, and that neurological progress could be pre-vented to some extent even in severe form. Conclusion: Our study
confirmed the efficacy of HSCT in selected patients with IEM in
early stages. A detailed comparison in Hunter’s disease with un-
transplanted patients suggested the efficacy of HSCT even in severe
form, but the neurological effect seemed to be less than that in
Hurler’s disease (MPS IH).193
OSTEONECROSIS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
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Dana-Farber Cancer Institute, Boston, MA.
Background: Osteonecrosis (ON) is a potentially devastating
complication of pediatric hematopoietic stem cell transplantation
(HSCT).We report the frequency of symptomatic ON in pediatric
patients (pts) who underwent allogeneic HSCT at Children’s Hos-
pital Boston/Dana-Farber Cancer Institute over a 6-year period.
Methods: We retrospectively reviewed the medical records of
293 consecutive pts who underwent 307 allogeneicHSCTs between
January 1, 2000 and December 31, 2006. Diagnosis of ON was
based on patient symptoms and confirmed by review of the attend-
ing radiologist’s final reading of at least one radiographic study.Re-
sults: A total of 15 pts (5.1%) developed symptomatic ON.
Underlying diagnoses included 5 pts with acute lymphoblastic lym-
phoma (ALL), 3 acute myeloid leukemia, 1 myelodysplastic syn-
drome, 3 chronic myeloid leukemia, 2 aplastic anemia, and 1
sickle cell disease. Eleven pts underwent unrelated donor HSCT
and 4 had matched sibling transplants. Eleven pts (73%) were
$10 years of age at the time of HSCT. Thirteen (87%) developed
chronic graft-versus-host disease (GVHD), 9 of whom received ste-
roids for over 12 months. The 2 pts without chronic GVHD had an
underlying diagnosis of ALL. Two pts underwent a second alloge-
neic HSCT for relapsed disease and developed ON only after the
second transplant. One pt was diagnosed w/ON prior to HSCT
with ON that worsened significantly post HSCT. With regard to
sites of ON, only 2 pts had a single site (unilateral hip and unilateral
knee). Six pts developed bilateral ONof the hips. Of these, 2 pts also
had bilateral knee ON (one also with ON of the sacrum). Five ad-
ditional pts developed bilateral ONof the knees and 2 pts developed
bilateral ON of the ankles. Two pts underwent surgical interven-
tions; 1 pt underwent core decompression for bilateral knee ON,
and the other, arthroscopy with debridement and drilling of the ta-
lus for extensive ankle involvement. Eight of the 15 pts are currently
surviving. Four pts are known to have persistent complaints of joint
pain.Conclusion: Symptomatic ON developed in 5.1% of pts who
underwent allogeneicHSCT. Themajority of pts with ONwere af-
fected at multiple sites. Further interventional and follow-up studies
aimed at identifying those at greatest risk, preventing the complica-
tion, and decreasing morbidity fromON are needed in the pediatric
HSCT population.194
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Background: A high dose of busulfan (BU) combined with ther-
apeutic drug monitoring as been suggested to be associated with
higher event free survival (EFS) rates due to less graft-failure/re-
lapses and lower toxicity. Since 2001 we (LUMC and UMCU)
are using intravenous BU in various myelo-ablative regimen: we
have targeted to various area’s under the curve (AUC) and have
given BU either once daily or 4 times a day. In this study we retro-
spectively analysed the association between busulfan exposure
